

Eckert & Ziegler SE
Dr. Harald Hasselmann, CEO

9M results 2026
November 12, 2026

The independent supplier of medical isotopes and manufacturing services to the radiopharmaceutical industry

Frankfurt Stock Exchange (Prime Standard) · Ticker EUZ · ISIN DE0005659700 · SDAX / TecDAX

Disclaimer

This presentation contains forward-looking statements based on the beliefs of Eckert & Ziegler SE management. Such statements reflect current views of Eckert & Ziegler SE with respect to future events and results and are subject to risks and uncertainties. Actual results may vary materially from those projected here, due to factors including changes in general economic and business conditions, the introduction of competing products, lack of market acceptance of new products, services or technologies and changes in business strategy. Eckert & Ziegler SE does not intend or assume any obligation to update these forward-looking statements.

The provision of presentations or recordings of webinars is exclusively for internal, business use. Presentations or recordings of webinars may only be passed on to third parties or reproduced with the prior written consent of Eckert & Ziegler SE. The independent production of recordings as well as their subsequent transfer to third parties also requires the prior written consent of Eckert & Ziegler SE.

All information contained in this presentation or webinar is provided without guarantee of accuracy, completeness or currency. Any contractual obligation and/or liability in connection with the presentation or webinar, including vis-à-vis third parties, is excluded. Slides only for illustration, the spoken word shall be binding.

Why invest in Eckert & Ziegler: the independent isotope supplier to a market growing about 15% a year

15% p.a.

A structural growth market with a supply bottleneck

Nuclear medicine is expected to grow from USD 11.bn (2024) to USD 26.bn (2030e), driven by radioligand therapy. About 300 clinical trials with new targets use Ga-68, Lu-177, Ac-225, Y-90 and Pb-212, and every one of them needs a qualified isotope supplier.

48+ months

Independent and hard to replace

No drug pipeline of our own, so every developer is a potential customer. 48+ months from announcement to first commercial batch; 6+ months and a regulatory variation to switch supplier; GalliaPharm® supplied to 50+ countries.

per procedure

Recurring, reimbursed demand

One dose per scan or treatment cycle, paid per procedure and non-deferrable. Patient volumes do not follow the economic cycle. About 50% of group revenue is related to radiopharmaceuticals.

29% CAGR

A proven growth engine funded by a cash-generative base

Radiopharmaceutical revenue grew from EUR 18.5m (2017) to EUR 145.5m (2025). The other half of the group (industrial, imaging and laboratory isotopes) is a stable, high-margin business that funds capacity investments without dilution. Adjusted EBIT margin 25% (FY2025), ROCE 17–20%, net cash about EUR 100m.

EZ delivers as promised

2026 is a transition year, and the catalysts are dated

Reported growth is flat because 2025 contained EUR 14.4m of near-full-margin license income; **Capital Markets Day 13 April 2027**.

Eckert & Ziegler at a glance: EUR 312m sales, 25% adjusted EBIT margin (2025)


Eckert & Ziegler SE produces and distributes radioisotopes and related equipment for medicine, industry and science. The Medical segment (55% of 2025 sales, 30% adjusted EBIT margin) supplies pharmaceutical-grade isotopes, Ga-68 generators and contract development and manufacturing to radiopharmaceutical developers, as well as brachytherapy products. The Isotope Products segment (45% of sales, 19% margin) supplies sealed sources, equipment and services for medical imaging, industrial measurement, calibration, laboratories and the recycling of radioactive sources. The group is headquartered in Berlin, produces in Germany the USA and Latin America and, from 2027, in China, and serves customers in more than 50 countries. The company has been listed in Frankfurt since 1999.






2025: EUR 312m sales, 25% adjusted EBIT margin

Sales 2025



Adj. EBIT 2025



Medical Isotope Products

( ) = vs. prior year	Sales (ext.)		EBIT adj. / -margin			Employees (Dec 2025)	
Group	**EUR 312,0m**	(+5%)	**EUR 77,7m**	(+18%)	**/ 25%**	**1.116**	(+3%)
Medical	EUR 171,0m	(+15%)	EUR 51,1m	(+29%)	/ 30%	428	(+3%)
Isotope Products	EUR 140,9m	(-4%)	EUR 28,3m	(-9%)	/ 20%	608	(+3%)

32,4m / 10% (-34%)
Free cash flow / -margin


128,8m (+9%)
Cash balance and securities

55% (+4,4 pp)
Equity ratio


0,22 (+29%)
Dividend per share (EUR)

9M 2026: EUR 229m sales, 23% adjusted EBIT margin

Sales 9M 2026



Adj. EBIT 9M 2026



Medical Isotope Products

( ) = vs. prior year	Sales (ext.)		EBIT adj. / -margin			Employees (Sep 2026)	
Group	**EUR 229,0m**	(+2%)	**EUR 52,6m**	(+4%)	**/ 23%**	**1.131**	(+2%)
Medical	EUR 121,4m	(+1%)	EUR 36,2m	(+16%)	/ 30%	437	(+2%)
Isotope Products	EUR 107,5m	(+3%)	EUR 17,9m	(-11%)	/ 17%	613	(+1%)


16,7m / 7% (-25%)
Free cash flow / -margin

120,9m (0%)
Cash balance and securities


57% (+5,9 pp)
Equity ratio

Q3 2026: EUR 80m sales, 24% adjusted EBIT margin

Sales Q3 2026



Adj. EBIT Q3 2026



Medical Isotope Products


( ) = vs. prior year	Sales (ext.)		EBIT adj. / -margin			Employees (Sep 2026)	
Group	**EUR 79,7m**	(+6%)	**EUR 19,3m**	(+25%)	**/ 24%**	**1.131**	(+2%)
Medical	EUR 40,6m	(+4%)	EUR 11,3m	(+46%)	/ 28%	437	(+2%)
Isotope Products	EUR 39,1m	(+8%)	EUR 8,6m	(+9%)	/ 22%	613	(+1%)

13,7m / 17% (+53%)
Free cash flow / -margin

120,9m (0%)
Cash balance and securities

57% (+5,9 pp)
Equity ratio


Core Competences - Radioisotope Supply, Related Services and Equipment



Services and Equipment provided by Eckert & Ziegler

The Nuclear Medicine Market – Significant increase in demand expected

Estimated Nuclear Medicine Market Size 2030: **26BN USD** *



* MedRays Intell 2025


The Nuclear Medicine Market – Numerous large investments demonstrate huge potential



Selected financing rounds & investments 2023 – 2026

* MedRays Intell 2025

The Nuclear Medicine Market – Numerous large investments demonstrate huge potential



Selected financing rounds & investments 2023 – 2026

* MedRays Intell 2025

Core competences meets market developments

Gallium-68

“The Companion Diagnostic Isotope”

- Market Leader in Ga-68 generators
- Approval in EEA, USA and key international markets
- Prerequisite for therapy patient selection

Lutetium-177

“The Therapeutic Isotope of the Moment”

- EMA approval Q4/2024
- Broadly used (Pluvicto & Lutathera)
- Further drug products and indications to be approved soon



Yttrium-90

“Pushing Medical Devices”

- Global core supplier for Y-90
- APAC expansion ongoing

Actinium-225

“The Next Big Therapy Isotope”

- Pioneer: GMP grade in 2026
- Various trials ongoing with first commercial drug in 2028

Equipment & Services

“Facilitators & Enablers”

- Global radiopharmaceutical manufacturing
- Provision of infrastructure & equipment incl. hot cells

Core Competences – Enabling partners to develop and supply innovative radiopharmaceuticals *

^{177}Lu

- Lilly
- POINT BIOPHARMA
- Telix
- alpha9 ONCOLOGY
- Ratio THERAPEUTICS
- GI Therix
- Nucleus RadioPharma
- AtomVie Global RadTopharma

^{225}Ac

- Lilly
- POINT BIOPHARMA
- alpha9 ONCOLOGY
- Telix
- FULL-LIFE TECHNOLOGIES
- Nucleus RadioPharma
- Ratio THERAPEUTICS
- PharmaLogic
- Actinium Pharmaceuticals, Inc.
- GI Therix
- SK biopharmaceuticals

Contract Manufacturing

- Bicycle
- Telix
- ARCHEUS
- OncoSil MEDICAL
- MOLECULAR partners
- PENTIXAPHARM

*For confidentiality reasons, only a selection of our customers can be mentioned. The list also shows those with reservation agreements only.

Lu-177: broad commercial access built on an integrated supply platform

Indication*	2025		2030	
	Patients	Lu-177 Sales	Patients	Lu-177 Sales
Prostate Cancer	≈ 13.000	> 104 Mio. EUR	≈ 65.000	> 520 Mio. EUR
Neuroendocrine Tumors	≈ 6.800	> 54 Mio. EUR	≈ 10.000	> 80 Mio. EUR

*taking into account the indications for which market-approved products are currently available

Independent supply & manufacturing partner — no own drug pipeline, no competing programs

1

Direct to developers

Eli Lilly / POINT: 10-yr · > €100m

Telix · Alpha-9 + others

across all development stages

2

Integrated E&Z CDMO

Telix ProstACT · Phase III

isotope + drug-product manufacturing

3

Third-party CDMOs

AtomVie · Nucleus

into partners' manufacturing

4

Direct to hospitals

Own EU presence since 2026

(market size > €30m)

n.c.a. Lu-177 Supply Platform

High purity · EU GMP Facility today · US GMP Facility in 2027

Selected public examples; not exhaustive. Contract volumes may depend on regulatory approval. US GMP timing is a forward-looking target.

Ac-225: securing supply and broad partner access to a scarce alpha-emitter

Indication*	2029		2034	
	Patients	Ac-225 Sales	Patients	Ac-225 Sales
Prostate Cancer	≈ 5.000	> 90 Mio. EUR	≈ 12.000	> 192 Mio. EUR
Neuroendocrine Tumors	≈ 500	> 9 Mio. EUR	≈ 800	> 12,8 Mio. EUR

*taking into account the indications for which clinical trials are most advanced

Independent supply & manufacturing partner — no own drug pipeline, no competing programs

1

Direct to developers / pharma

Lilly / POINT · SK Biopharmaceuticals
Full-Life · Actinium Pharmaceuticals
GlyTherix · Alpha-9 · Molecular Partners
Ac-225 supply, clinical / dev programs

2

Technology licensing

Telix — cyclotron Ac-225 method
up to €20m
monetizing proprietary production IP

3

CDMO — own & partners

E&Z GMP manufacturing
PharmaLogic · Nucleus
isotope + drug-product services

Proprietary Ac-225 supply platform

own production · cyclotron-based technology · Alpha Labs (Berlin, Braunschweig)
Sites: EU today · China (Jintan) in build-up
Regulatory: GMP scale-up · US DMF planned 2026

Selected public examples; not exhaustive. Ac-225 programs are pre-commercial (clinical / R&D). Milestone payments, GMP scale-up and US DMF timing depend on execution and regulatory steps.

A partner for the entire industry, not just for a single product

Product and process development

Higher activity, better yields, longer shelf life

Capacity and redundancy

Opening additional production lines and sites

Portfolio broadening

Further diagnostic and therapeutic isotopes across the value chain

Building a portfolio around a nuclide e.g. Ga-68 with automation solutions or QC

Strategic position as partner of choice

Early engagement, long-term integration into the clinical development cycle (e.g. via CDMO), true partnership on equal footing – not just supply



Recurring, Partially Reimbursed, Global – not Medtech Capex

Radionuclides are **required for all targets.**
Demand follows patient volumes, not economic cycles.

Dose required per procedure

Paid/Reimbursed per scan or treatment cycle

Recurring and non-deferrable

In weak economic cycle: patient volumes are unchanged

+15 %

Expected CAGR of the market until 2030

(MedRays Intell 2025)

~300

Ongoing clinical trials with **new targets** using Ga-68, Lu-177, Ac-225, Y-90, Pb-212

PSMA, NET not included
(ancora.ai, Sep 17, 2026)

~50%

Share of group revenue related to radiopharmaceuticals

(Annual Report 2025)



Hard to Enter, Harder to Replace – Eckert & Ziegler is well positioned in Ga-68 / radioisotopes

48+ months*
estimated lead time from announcement to first commercial batch

Market Entry Barriers

- ✓ Licenses and permits
- ✓ GMP certification and inspection
- ✓ Customer qualification and audits
- ✓ Reference in dossiers
- ✓ Qualified Workforce

min. 2
qualified upstream sources worldwide

Scarcity sits upstream

- ✓ Access to gated parent material / targets
- ✓ Access to irradiation capacity
- ✓ Long-term feedstock agreements
- ✓ Vertical integration where appropriate

6+ months*
to qualify an alternative supplier

Switching Costs are regulatory

- ✓ Products are referenced in customer filings
- ✓ Change often requires regulatory variation
- ✓ Comparability, stability, QC requalification

50+ countries
GalliaPharm® is supplied to

Reliability and Contracts

- ✓ Global sales network
- ✓ Multi-year supply agreements where possible
- ✓ Deep service and after-sales integration
- ✓ Reliability premium on short half-lives

*EZ experience-based

Latest Highlights

October 2026



Eckert & Ziegler Receives Ac-225 GMP Certificate

Competent German authority confirms Actinium-225 facility meeting GMP requirements, facilitating the radioisotope's use for investigational treatment of patients.

October 2026



Supply Agreement for GMP Tb-161 TerThera

The partnership establishes a critical and reliable supply chain for Terbium-161 in South America, in particular in Brazil.

September 2026



Inauguration of new facility in Brazil

Opening of a state-of-the art prodcution site for Technetium-99m cold kits, with room for CDMO partnerships in inactive sterile injectables and lyophilized products.

Group: Solid 9M performance – strong Q3, outlook positive (in Mio. EUR)

Net Sales




- FX adjusted: +3%
- Radiopharmaceuticals continue to grow (+5% vs. 9M 2025), **+11%** adjusted for license deal in Q1 2025, no license revenue in 2026 yet
- Medical slightly above the 2025 level (+1%), no license revenue yet, strong Radiopharma business, lowlight: Engineering
- Isotope Products: 3P sales improved, 3% on PY (H1 was +0% vs. PY), still below expectations, lowlight: Ind./OWL (-9m vs. PY)

EBIT adj.



- Medical: favorable product mix compensates high margin license in 2025
- Isotope Products: momentum continued in Q3, outlook optimistic
- Others: -1,0 Mio. vs. PY -> retrospective adjustment of the equity-based remuneration under the LTI bonus scheme (partially one-time effect)


EBIT adj. margin



- 2025: Extraordinary effect restoration of IT infrastructure -1,5 Mio. EUR
- Financial result & currency effects: 0,6 Mio. EUR (PY: -1,0 Mio. EUR)
- Hyperinflation -0,7 (PY: -0,7 Mio. EUR)
- Net Income: 35,4 Mio. EUR (PY: 29,9 Mio. EUR; +19%)
- EPS: 0,57 EUR; PY: 0,48 EUR (+19%)

9M 2026: adjusted EBIT +14% excluding the 9M 2025 income

Adjusted EBIT bridge 9M 2025 → 9M 2026 (EUR m)



Sales

EUR 229,0m, +2% reported (**+4% excl. license income**).
Radiopharmaceuticals +5% reported (**+11% excl. license income**).

Earnings

Adj. EBIT EUR 52,6m (+4%; **+14% excl. license income**)
Ebit adj. margin 23% (+0pp; **+2pp excl. license income**).

Medical

Sales +1% to EUR 121,4m (**+6% excl. license income**)
Adj. EBIT +16% to EUR 36,2m (**+38% excl. license income**)
EBIT adj. margin 30% (+4pp; **+7pp excl. license income**)

Group revenue: USA remains largest market, Europe grows steadily, Asia distorted by 2025 license deal

Europe



+7%



- Largest markets: Germany 27 Mio. EUR (+12%), followed by UK/IRL 13 Mio. EUR (+6%) and Scandinavia 8 Mio. EUR (-7%)
- Strongest abs. growth in Switzerland/Austria +3 Mio. EUR and Germany + 3 Mio. EUR

Americas



0%




- USA **largest market worldwide**, 75 Mio. EUR (-5%, hot cell project in H1 2025)
- South America 20 Mio. EUR (+10%)
- Canada 5 Mio. EUR (+121%)

Asia




-14%



- China 7 Mio. EUR (-46%; license deal in Q1 2025; 5 Mio. EUR)
- Rest of Asia 25 Mio. EUR (+3%)

Middle East & Africa



+57%



- good growth, but still at a low level
- increase mainly due to hot cell project

Medical: top line on prior year, earnings driven by favorable product mix, despite no licenses in 2026 yet (in Mio. EUR)

Net Sales (external only)



EBIT adj.



EBIT adj. margin





- FX adjusted: +3%
- Highlights: strong development in CDMO +57% and Lu-177 sales +280%, Y-90 +33% and +5% in generators
- Ac-225: 2025 contained license deal with China JV (5 Mio.), no respective revenue in 9M 2026
- Engineering -40%, completion of major projects in H1 2025, shift towards intercompany projects, weaker overall order situation

- Gross profit: 62,1 Mio. EUR, +4,5 Mio. EUR vs. PY (+8%)
- Gross margin: 51%, +3pp vs. PY (despite license deal with China JV in 2025 - high margin)
- EBIT effect from license deal: none in 9M 2026 but 4,8 Mio. EUR in Q1 2025


- Financial result and currency effects: -0,1 Mio EUR (PY: -1,1 Mio. EUR)
  - thereof currency effects: 0 Mio. EUR (PY: -0,8 Mio. EUR)
- Interest -0,7 Mio EUR (PY: -0,6 Mio. EUR)
- Net Income 23,9 Mio EUR (PY: 18,3 Mio. EUR; +31%)

Isotope Products: momentum continued in Q3, product mix improved - outlook optimistic (in Mio. EUR)


Net Sales (external only)



EBIT adj.



EBIT adj. margin





- FX adjusted +4%
- Strong performance in Medical Imaging Business (+44%) and HARS (+59%) -> completion of a large Co-60 installation project (catch-up effect)
- Industrial (incl. OWL) (-28%), Isotrak (-7%) and Isotope sales (-21%) way below PY (high margins), SPECT (+12%) (lower margins)
- After Q1 being -7% vs. 2025, the regained momentum from March remained through Q2 (+7% vs. Q2 2025) and **Q3 (+8% vs. Q3 2025)**


- Gross profit: 49,2 Mio. EUR -0,0 Mio. EUR vs. PY (0%)
- Gross margin: 43%, PY: 44%
- Product mix hast improved over the course of the year -> positive gross margin trend (Q1: 40%; Q2: 42%; Q3: 47%)
- EBIT adj. in **Q3**: 8,6 Mio. EUR (PY: 7,8 Mio. EUR; +9%)

- Financial result and currency effects: 0,6 Mio EUR (PY: 0,2 Mio. EUR)
  - thereof currency effects: 0,1 Mio. EUR (PY: -0,2 Mio. EUR)
- -0,7 Mio. EUR Hyperinflation (IAS 29) (PY: -0,7 Mio. EUR)
- Interest -0,8 Mio EUR (PY: -0,3 Mio. EUR)
- Net Income 12,5 Mio EUR (PY: 12,5 Mio. EUR; -1%)

Radiopharmaceuticals to grow by 5% (9M 2026 vs. 9M 2025, in Mio. EUR) / +11% adjusted for licenses

Radiopharmaceuticals:

- Pharmaceutical grade bulk radioisotopes (Y-90, Lu-177, Ac-225)
- Pharmaceutical grade generators (Ga-68, Tc-99)
- Cold Kits
- Contract development services
- Contract manufacturing services
- Radiopharmaceutical production equipment



Radiopharmaceuticals to grow by 5% (9M 2026 vs. 9M 2025, in Mio. EUR) / +11% adjusted for licenses



EBIT adj. (+4% vs. 9M 2025)

in Mio. EUR	Medical		Isotope Products		Others		Total	
	9M/2026	9M/2025	9M/2026	9M/2025	9M/2026	9M/2025	9M/2026	9M/2025
EBIT reported (from continuing operations)	**36,1**	**29,8**	**17,9**	**18,8**	**-1,4**	**-0,9**	**52,6**	**47,6**
financial result	0,2	0,3	-0,6	-0,4	-0,1	0,1	-0,5	0,0
currency effects	0,0	0,8	-0,1	0,2	0,0	0,0	-0,1	1,0
IAS29 (hyperinflation)	0,0	0,0	0,7	0,7	0,0	0,0	0,7	0,7
acquisition	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
divestment	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
impairment losses	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
restructuring	0,0	0,2	0,0	0,9	0,0	0,3	0,0	1,5
EBIT adjusted	**36,2**	**31,1**	**17,9**	**20,2**	**-1,5**	**-0,5**	**52,6**	**50,8**

“EBIT before special items from continuing operations“ (short: EBIT adjusted) will be used as a second performance indicator in addition to sales, instead of net profit for the year. The focus on these two parameters provides a **better assessment of the operating performance of the core business** excluding special items, i.e. without effects that are special in terms of their nature and amount for the management of the Group. These include financial and currency results, losses in accordance with IAS 29 (hyperinflation), acquisition costs, divestments, impairment losses or restructuring. When calculating this key figure, the EBIT is increased by extraordinary expenses and reduced by extraordinary income.

Strong Balance Sheet as of 30 September 2026: Equity ratio 57%

Cash/Stocks	121	Equity	284
Receivables	51	Minority Interests	1
Inventory	50	IFRS 16 Leasing	30
IFRS 16 Leasing	27	Accruals/Provisions	101
Intangible Assets	49	Loan liabilities	9
Fixed Assets	113	Other Short Term Payables	62
Assets held for sale	0	Other Long Term Payables	10
Others	85	Liabilities related to assets held for sale	0
Total Assets	**497**	**Total Liabilities**	**497**

Key Figures

	9M 2026 in Mio. EUR	9M 2025 in Mio. EUR	Changes to PY in %
EBIT adjusted	52,6	50,8	+ 3,6
Cash flow from operating activities[1]	30,8	39,7	- 22,3
Payments for intangible assets and property, plant and equipment[1] [2]	14,1	17,3	- 18,4
FCF-Margin	7%	10%	-2,7 pp
ROCE	17%	18%	-1,6 pp
Cash and Cash equivalents and securities[1]	120,9	121,0	- 0,1
Loan Liabilities	8,8	15,0	- 41,3
Equity ratio	57%	52%	+5,9 pp
Headcount	1.131	1.112	+ 1,7

[1] from continuing operations only

[2] change to previous publications: was "Cash flow from investing activities" in the Cash Flow Statement referred to as "Investments" now "payments for intangible assets and property, plant and equipment"

Outlook: Guidance 2026 remains unchanged

in Mio. EUR	2025	2026 Guidance	Change to PY	
			abs.	in %
Net Sales (Group)	**312**	**320**	**+ 8**	**+3%**
EBIT adjusted	**78**	**80**	**+ 2**	**+3%**
Medical		49	- 2	-4%
Isotope Products		33	+ 5	+17%
Others		-2	- 0	+23%
thereof Ac-225 License Deals				
Sales	*14,4*	*5,6*	*- 8,8*	*-61%*
EBIT	*14,0*	*5,5*	*- 8,5*	*-61%*
exchange rate EUR 1 = USD … (average)	*1,13*	*1,20*	*+ 0,07*	*+6%*

guidance remains unchanged

Financial calendar and IR-contact

2026

- Nov 17 Jefferies Healthcare Conference, London
- Nov 23-25 German Equity Forum, Frankfurt
- Dec 1 mwb German Select (virtual)
- Dec 10 CIC CIB Forum 2026 (virtual)
- Dec 11 NuWays Healthcare Day (virtual)

2027

- Jan 18 German Corporate Conference (gcc), Frankfurt
- Mar 24 Annual Financial Statements
- **Apr 13 Capital Market Day, London**
- May 12 Quarterly Report I/2027
- May 25 Berenberg European Conference, Manhattan
- Jun 16 Annual General Meeting
- Aug 12 Quarterly Report II/2027
- Sep 20-22 Berenberg & Goldman Sachs Germ. Corp.Conf., Munich
- Nov 11 Quarterly Report III/2027
- Nov 15-16 Jefferies Global Healthcare Conference, London
- Nov 22-24 German Equity Forum, Frankfurt

(subject to changes)

Eckert & Ziegler SE
Karolin Riehle
Investor Relations & PR

Robert-Rössle-Str. 10
D-13125 Berlin
Tel. +49 30 94 10 84-138

karolin.riehle@ezag.de
www.ezag.de
ISIN DE0005659700

Group Executive Committee – Leading expert teams with extensive experience in key areas



Dr. Harald Hasselmann
CEO



Dr. Gunnar Mann
Member of the Executive Board



Frank Yeager
Chief Executive Officer
(Isotope Products)



Joe Hathcock
Chief Operating Officer
(Isotope Products)



Richard Hunter
Vice President Sales & Marketing
(Isotope Products)



Ana Ramirez
Vice President Regulatory & Quality Operations (Isotope Products)



Dr. Dirk Becker
Vice President Research & Development
(Medical)



Lars Flemmig
Vice President Strategy China
(Medical)



Julian Schröder
Head of Group Controlling



Thank you!

Eckert & Ziegler
Contributing to saving lives

